Industry profile · NAICS 325413

Blood derivative in-vitro diagnostic substances manufacturing

Workplace injury rates across 232 OSHA-reporting establishments in this industry, 2016–2024.

232
Employers
2.0
Avg TCR
3.3
BLS benchmark
3,606
Injuries

The industry picture

Employers in Blood derivative in-vitro diagnostic substances manufacturing average 2.0 recordable injuries per 100 workers, below the BLS national benchmark of 3.3.

2.0
avg TCR · reporting employers
3.3
BLS national benchmark
232
employers reporting
3,606
recordable injuries

OSHA-reporting establishments skew toward larger, higher-hazard sites, so the reporting average runs above the BLS all-establishment benchmark.

What Blood derivative in-vitro diagnostic substances manufacturing Safety Data Reveals

The Blood derivative in-vitro diagnostic substances manufacturing sector (NAICS 325413) encompasses 232 distinct employer establishments currently reporting to OSHA's Injury Tracking Application. Across this cohort, workers have logged 3,606 recordable injuries during the 2016–2024 reporting window, producing an industry-weighted average Total Case Rate (TCR) of 2.0 injuries per 100 full-time workers per year. Because OSHA's ITA mandates submission from establishments with 250+ employees plus all high-hazard industries at 20+ employees, this dataset represents a structural slice of U.S. workplace risk rather than a voluntary sample.

The Bureau of Labor Statistics publishes a separate national benchmark TCR of 3.3 for this NAICS code, derived from the BLS Survey of Occupational Injuries and Illnesses. Comparing the two, the ITA-reported rate of 2.0 is below the BLS benchmark, a gap that typically widens when the industry contains many large, high-exposure establishments required to file ITA reports. Employers in the table below are sorted so you can see how far individual establishments deviate from both the industry average and the national benchmark.

The practical value of industry-level safety data is threefold. First, jobseekers can gauge whether a prospective employer is better or worse than its industry peers, not just absolute injury counts, which tilt toward larger payrolls. Second, insurers and workers' compensation carriers use sector TCR as a baseline for experience-modification adjustments. Third, safety professionals benchmark their own programs against the cohort median. Use the grade-sorted employer list below to identify specific establishments within Blood derivative in-vitro diagnostic substances manufacturing that outperform or underperform the sector average, and click through to each record for year-by-year injury, illness, and fatality breakdowns.

Employers in this industry, by injury rate

Page 4 of 5
Employer LocationGradeAvg TCR
Thermo Fisher Scientific Pleasanton Sunol Facility Pleasanton, CA A 0.9
Walpole Site East Walpole, MA A 0.8
DL Woburn Woburn, MA A 0.8
Ventana Medical Systems Oro Valley, AZ A 0.8
Promega Corporation San Luis Obispo, CA A 0.8
IDEXX World Campus Westbrook, ME A 0.8
Poly Scientific R&D Corp Bay Shore, NY A 0.8
CMI San Diego Mesa Rim San Diego, CA A 0.8
Visby Medical, Inc. San Jose, CA A 0.8
Illumina Madison, WI A 0.8
Cepheid Bothell, WA A 0.8
Diagnostic Hybrids - Athens, OH Athens, OH A 0.8
Thermo Fisher Scientific Middletown, VA A 0.7
BioMerieux Durham Durham, NC A 0.7
ARDx Gurnee J54 Gurnee, IL A 0.7
Riverside Facility Andover, MA A 0.7
Mediatech Manassas, VA A 0.7
ProteinSimple San Jose, CA A 0.7
Trividia Health Inc - 2200 Fort Lauderdale, FL A 0.7
Thermo Fisher Scientific Eugene, OR A 0.7
Fujirebio Malvern Malvern, PA A 0.7
EnviroLogix Inc. Portland, ME A 0.7
Thermo Fisher Scientific Carlsbad, CA A 0.7
Los Angeles Site Los Angeles, CA A 0.7
SA Scientific Ltd. San Antonio, TX A 0.6
bioMerieux St. Louis Hazelwood, MO A 0.6
Techlab Inc Blacksburg, VA A 0.6
Becton Dickinson Caribe LTD. Biosciences Cayey, PR A 0.6
Immucor Warren Warren, NJ A 0.6
Becton Dickinson Integrated Diagnostic Solutions Baltimore Sparks, MD A 0.6
SeraCare Life Sciences, Inc. Milford, MA A 0.5
LGC Clinical Diagnostics, Inc. MA Milford, ME A 0.5
CMI Carlsbad Carlsbad, CA A 0.5
Thermo Fisher Scientific Lenexa, KS A 0.5
Kova Garden Grove, CA A 0.5
bioMerieux Inc. Hazelwood, MO A 0.5
QuidelOrtho McKellar San Diego, CA A 0.4
Ortho Clinical Diagnostics CNP 130 Rochester, NY A 0.4
ARDx San Diego Ameditech San Diego, CA A 0.4
Bio-Rad Laboratories-Plano Plano, TX A 0.4
Ortho Clinical Diagnostics - Rochester Canal Ponds Rochester, NY A 0.4
Cerilliant Corporation Round Rock, TX A 0.4
Moravek Inc. Brea, CA A 0.4
Ortho Clinical Diagnostics CNP100 Rochester, NY A 0.4
QuidelOrtho Raritan Raritan, NJ A 0.3
ARDx San Diego Mesa Rim (Tox) San Diego, CA A 0.3
Sigma-Genosys of Texas, LLC The Woodlands, TX A 0.3
Agena Bioscience, Inc. San Diego, CA A 0.3
bioMerieux Commercial Operations Durham, NC A 0.3
Thermo Fisher Scientific Pleasanton Pleasanton, CA A 0.2
← Prev Page 4 of 5 Next →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainSafetyScore Editorial

Verify with BLS →

Verify with OSHA →

Working in Blood derivative in-vitro diagnostic substances manufacturing?

This sector averages 2.0 against a BLS benchmark of 3.3 - but individual employers span the full A-to-F range.

Sector figures use the credible-subset mean across reporting employers; a benchmark is not any single establishment's measured rate.

Every figure and grade on PlainSafetyScore is computed directly from OSHA's published Injury Tracking Application data and BLS industry benchmarks, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these safety grades, or report a data error. Data current as of 2016-2024 OSHA ITA release.